We are live on ! Find out more

1,341 hedge funds and large institutions have $98.5B invested in Amgen in 2014 Q4 according to their latest regulatory filings, with 187 funds opening new positions, 449 increasing their positions, 509 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more first-time investments, than exits

New positions opened: 187 | Existing positions closed: 54

32% more funds holding in top 10

Funds holding in top 10: 76100 (+24)

13% more capital invested

Capital invested by funds: $86.9B → $98.5B (+$11.6B)

10% more funds holding

Funds holding: 1,2231,341 (+118)

12% less repeat investments, than reductions

Existing positions increased: 449 | Existing positions reduced: 509

23% less call options, than puts

Call options by funds: $1.06B | Put options by funds: $1.38B

Holders
1,341
Holders Change
+118
Holders Change %
+9.65%
% of All Funds
35.62%
Holding in Top 10
100
Holding in Top 10 Change
+24
Holding in Top 10 Change %
+31.58%
% of All Funds
2.66%
New
187
Increased
449
Reduced
509
Closed
54
Calls
$1.06B
Puts
$1.38B
Net Calls
-$318M
Net Calls Change
-$307M

AMGN Hedge Fund Activity: Q4 2014 in Review

1,341 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Amgen (AMGN) for Q4 2014, worth a combined $98.5B — up 13% from $86.9B a quarter earlier.

Buyers outnumbered sellers: 187 funds opened new AMGN positions and 54 closed out — a net gain of 133 holders — while 449 added to existing stakes and 509 trimmed.

The largest buyer was Third Point, adding an estimated $1.46B. The largest seller was Goldman Sachs, cutting an estimated $484M.

  • 1,341 institutional investors held Amgen (AMGN) as of Q4 2014, up from 1,223 in Q3 2014.
  • Funds reported $98.5B of Amgen stock for Q4 2014, up 13% quarter-over-quarter.
  • 187 funds opened new Amgen positions in Q4 2014 and 54 closed out, a net change of +133 holders.
  • The largest Amgen buyer in Q4 2014 was Third Point, an estimated $1.46B added.
  • The largest Amgen seller in Q4 2014 was Goldman Sachs, an estimated $484M sold.

Based on aggregated 13F filings for Q4 2014.